What Cannabis Is
Cannabis — the genus encompassing Cannabis sativa, C. indica, and C. ruderalis, often hybridised beyond clear taxonomic distinction in commercial cultivation — is a flowering plant producing over 100 identified cannabinoid compounds, the most pharmacologically significant being delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the primary psychoactive compound; CBD is non-intoxicating and modulates THC's effects. The ratio of THC to CBD in commercial cannabis has shifted dramatically in recent decades: selective breeding for potency has produced products with much higher THC concentrations and lower CBD content than cannabis encountered in most of the twentieth century.
Cannabis is consumed by smoking, vaporising, oral ingestion (edibles), sublingual tincture, and topical application, with meaningfully different pharmacokinetic profiles across routes. Smoked and vaporised cannabis produces effects within minutes; edibles require 30–90 minutes to onset but can produce significantly more intense and longer-lasting effects than the same amount smoked, due to first-pass metabolism converting THC to 11-hydroxy-THC — a more potent compound with better CNS penetration.
Is Cannabis a Psychedelic?
This is a genuinely contested question. Cannabis does not fit the standard classification of “classic psychedelic” — it does not act primarily through 5-HT2A receptor agonism and its phenomenological character differs substantially from psilocybin, LSD, or mescaline. At low to moderate doses, its effects are more accurately described as sedating, anxiolytic, or mildly euphoric. However, at high doses — particularly with high-THC preparations taken orally — cannabis can produce experiences that are distinctly psychedelic in character: ego dissolution, time distortion, paranoia, visual phenomena, and a quality of expanded or altered awareness that qualifies as genuinely non-ordinary consciousness.
Cannabis has been described as an “entactogen” (at low doses, producing emotional openness and sensory enhancement), a mild anxiolytic, and — at high doses — as producing psychedelic states. Its effects are extraordinarily dose-dependent: a dose that produces mild relaxation in a regular user can produce a frightening dissociative experience in a naive user. This dose-dependence is more extreme with edibles, where onset delay leads many people to consume additional doses before the first has peaked, resulting in dramatically higher total intake than intended.
Within the psychedelic community, cannabis is often used as an adjunct to psychedelic experiences (see the Combinations section below), and some ceremonial traditions incorporate cannabis as a sacramental substance in its own right. The relationship between cannabis and the Psygaia framework's ecological themes is interesting: cannabis has been associated with enhanced nature-relatedness and sensory receptivity in some users and contexts, though the research here is far less developed than for classic serotonergic psychedelics.
History & Cultural Roots
Cannabis has a longer and more geographically distributed history of human use than almost any other psychoactive plant. Archaeological evidence for cannabis use in shamanic contexts in Central Asia dates to at least 2500 BCE; Cannabis sativa appears in the Chinese pharmacopoeia by 2700 BCE. In South Asia, cannabis as bhang — a drink made from cannabis leaves, milk, and spices — has been used in Hindu and Sufi spiritual practice for millennia, with specific association with the god Shiva. In Sub-Saharan Africa and the Caribbean, Rastafari developed as a spiritual movement explicitly centred on cannabis sacrament. Across Indigenous cultures in the Americas, cannabis use is historically less documented than that of native plants, though it arrived through European colonisation and was rapidly integrated in many contexts.
Western prohibition of cannabis began in the early twentieth century — spearheaded in the United States by the 1937 Marihuana Tax Act and solidified under the 1970 Controlled Substances Act — and spread internationally through US-driven treaty obligations. The contemporary legalisation movement in North America, Europe, and elsewhere represents the most significant policy reversal in the century of cannabis prohibition. As with psychedelics, the science of cannabis has been suppressed and distorted by prohibition in both directions: harms both overstated (for political reasons) and understated (by industry and advocates).
How Cannabis Works
Cannabis acts primarily through the endocannabinoid system — a diffuse modulatory system present throughout the brain and body, using endogenous cannabinoid ligands (anandamide and 2-AG) to regulate neurotransmission, inflammation, pain, mood, appetite, and memory. CB1 receptors, the primary CNS target of THC, are among the most densely expressed G-protein-coupled receptors in the brain — concentrated in the cortex, hippocampus, basal ganglia, and cerebellum — and their activation produces the characteristic psychoactive effects. CB2 receptors are more peripheral, principally involved in immune regulation.
THC acts as a partial agonist at CB1 receptors, mimicking anandamide but with longer duration and stronger effect at typical doses. Its psychoactive effects arise from disruption of normal endocannabinoid signalling: alterations in sensory processing, time perception, working memory, and prefrontal executive function. CBD acts as a negative allosteric modulator at CB1 receptors — it does not activate them directly but modifies how THC activates them, attenuating some of THC's psychoactive and anxiogenic effects. This is why high-CBD preparations are generally less anxiety-provoking and less psychoactive than high-THC preparations.
The subjective effects of cannabis are among the most powerfully shaped by expectation and set of any commonly used substance. Regular users develop significant tolerance to CB1-mediated effects; naive users can experience intense psychoactive effects at doses that produce little response in experienced users.
Effects
Low to moderate doses
At typical smoked or vaporised doses in experienced users: mild euphoria; relaxation or sedation; enhanced sensory perception (music, food, and touch often become more vivid and pleasurable); altered time perception (time slows subjectively); increased sociability or introspection depending on the individual and context; and mild short-term memory impairment. The classical stereotype of the relaxed, hungry, sociable cannabis user reflects low-to-moderate dose effects in tolerance-adapted individuals.
High doses
At high doses — or at any dose in naive users, particularly via edibles — effects escalate significantly: marked paranoia; intense anxiety or panic; pronounced dissociation (feeling separated from one's body or surroundings); visual phenomena; heart rate elevation that can reach levels that feel alarming; and in some cases, experiences indistinguishable in character from an acute psychotic episode. “Greening out” — cannabis-induced nausea and vomiting — is associated with very high doses, particularly in inexperienced users. Cannabinoid hyperemesis syndrome (CHS) — paradoxical recurrent vomiting in heavy long-term users — is a distinct and increasingly documented condition.
Edibles: a special case
Edible cannabis deserves special attention because the pharmacokinetic profile creates specific risks. Onset is delayed 30–90 minutes, and peak effects arrive 2–4 hours after consumption — much later than users who are accustomed to inhaled cannabis expect. Consuming additional product because “nothing is happening” at 45 minutes is the most common route to an unintended high-dose experience. 11-Hydroxy-THC, produced by hepatic metabolism of orally consumed THC, is more potent and longer-lasting than THC itself. A 10mg THC edible in a naive user can produce effects equivalent to much higher smoked doses.
What the Research Shows
Cannabis has a substantially larger clinical evidence base than most classic psychedelics, having been studied intensively despite (and sometimes because of) its contested legal status. Findings include:
Pain: The most consistent evidence supports cannabis for chronic pain, particularly neuropathic pain. A substantial body of randomised and observational evidence supports efficacy, and cannabis is used medically in this context across numerous legal jurisdictions.
Anxiety and PTSD: The picture is mixed and dose-dependent. Low-dose CBD and balanced THC/CBD preparations show anxiolytic effects in controlled studies. High-THC preparations can worsen anxiety and PTSD symptoms, and long-term heavy use is associated with increased rather than decreased anxiety. Observational studies from cannabis-for-PTSD programmes report symptom improvement, but methodological quality is generally limited.
Depression: No clear evidence supports cannabis as an antidepressant. Long-term heavy cannabis use is associated with increased risk of depressive episodes, particularly in individuals with genetic vulnerability. Short-term mood elevation from cannabis does not translate to therapeutic benefit for major depressive disorder.
Sleep: Cannabis reduces sleep latency and can help with short-term sleep difficulties, but long-term heavy use disrupts sleep architecture (particularly REM sleep) and is associated with reduced sleep quality after tolerance develops.
Psychosis risk: This is the area of clearest established harm. High-potency THC (above 10% concentration) is associated with elevated risk of psychotic episodes in vulnerable individuals, and regular use of high-THC products approximately doubles the risk of psychotic disorder in epidemiological studies (Di Forti et al., 2019). The risk is concentrated in people with genetic vulnerability (family history of psychosis), those who begin use in adolescence, and those who use high-potency products frequently. This risk is real and should not be minimised — it represents one of the most clearly established harms in the cannabis literature.
Cannabis & Other Psychedelics
Cannabis is among the most commonly used combination substances in psychedelic contexts. Its interaction with serotonergic psychedelics is significant and unpredictable enough to warrant specific attention.
At low doses during the descent or afterglow of a psilocybin or LSD experience, cannabis can re-intensify effects, extend the afterglow, and deepen reflection for some people. This is how many experienced psychedelic users incorporate it. At higher doses, or during the peak of a psychedelic experience, cannabis can tip effects from manageable to overwhelming — producing dramatic intensification of anxiety, paranoia, or dissociation. There are clear documented cases of people who would have navigated their psychedelic experience well who were pushed into acute psychiatric crisis by cannabis addition.
The mechanism is partly pharmacological (CB1 and 5-HT2A systems interact) and partly psychodynamic — cannabis amplifies whatever is already in the experiential space, positive or negative. For this reason, most harm reduction frameworks recommend avoiding cannabis during a psychedelic experience, particularly for inexperienced users, and treating its use in psychedelic contexts as a deliberate and informed choice rather than a casual addition. Timing matters: cannabis taken at the wrong moment of a psychedelic experience is not easily reversed.
Cannabis is explicitly discussed in the Psygaia Integration framework as a relevant consideration for ecological integration — its consumption habits represent an “ethics of attention and restraint” concern within the integration-as-lifeway model. This is not a moralising position about cannabis use in itself, but a recognition that how we attend to our daily intoxicant habits is part of relational and ecological practice.
Risks & Harms
Cannabis use disorder: Approximately 9% of people who ever use cannabis develop dependence; this rises to 17% among those who begin in adolescence and approximately 50% among daily users. Cannabis use disorder is real, involves tolerance, withdrawal (irritability, sleep disruption, appetite loss, anxiety), and craving, and represents an under-recognised public health issue as legalisation normalises heavy use.
Adolescent brain development: Regular cannabis use during adolescence — when the endocannabinoid system plays a critical role in brain development — is associated with persistent effects on executive function, memory, and mental health risk. This is among the most clearly established and most important harms in the cannabis literature. The relevant risk window extends to approximately age 25.
Respiratory harms from smoking: Combustion cannabis carries the same carcinogenic compounds as tobacco smoke and is associated with bronchitis and respiratory symptoms. Vaporisation eliminates combustion products and is meaningfully safer for the respiratory system than smoking.
Driving: Cannabis impairs reaction time, tracking ability, and decision-making and is associated with increased crash risk. The impairment window extends significantly beyond the subjective high, particularly with regular users who may feel sober while cognitively impaired.
Legal Status
Cannabis is undergoing a global regulatory transformation. Canada legalised recreational cannabis nationally in 2018 — the most comprehensive national legalisation framework in the world. In the United States, recreational cannabis is legal in 24 states and the District of Columbia; medical use is legal in 38 states; federal law still classifies it Schedule I, creating ongoing regulatory conflicts. Uruguay, Germany, Malta, Luxembourg, and the Netherlands (ongoing tolerance policy) have various forms of legalisation or decriminalisation in Europe. Most of Asia, Africa, and the Middle East maintain strict prohibition. Australia permits medical cannabis nationally and recreational use in the ACT. The legal landscape is changing rapidly and jurisdiction-specific verification is essential.
Frequently Asked Questions
Yes, cannabis can trigger psychotic episodes in vulnerable individuals, and regular use of high-potency THC products is associated with a significantly elevated risk of developing a psychotic disorder. The clearest risk factors are genetic vulnerability (family history of schizophrenia or bipolar disorder), early onset of use (adolescence), and frequency and potency of use. For people without these risk factors, the absolute risk is lower but not zero. High-potency THC products (above 10–15% THC) carry substantially more risk than lower-potency or balanced THC/CBD preparations. This harm is real, well-documented, and should not be dismissed by either advocates or critics of cannabis policy.
This is a decision that should be made deliberately and with full awareness of the risks. Cannabis reliably intensifies psychedelic experiences — whether that intensification is beneficial depends entirely on context, dose, the state you are already in, and your experience level with both substances. For inexperienced users, combining cannabis with any classic psychedelic significantly increases the risk of acute panic, paranoia, or a difficult experience becoming unmanageable. For experienced users who know their response to both substances, small amounts during the descent or afterglow can be useful for some people. The core harm reduction principle: if you are going to combine, use far less cannabis than you normally would, time it carefully, and have a sober sitter available.
Yes, cannabis produces physical and psychological dependence in a significant proportion of regular users. Cannabis use disorder — involving tolerance, withdrawal, and craving — affects approximately 9% of people who ever use cannabis and approximately half of daily users. The withdrawal syndrome (irritability, anxiety, sleep disruption, appetite loss) is real though less severe than alcohol or opioid withdrawal. The cultural tendency to dismiss cannabis addiction because it is “just weed” causes harm by preventing people from recognising and seeking help for a genuine problem.
The indica/sativa distinction that dominates cannabis retail has limited pharmacological validity. In modern commercial cannabis, the botanical distinction between C. indica and C. sativa has been so thoroughly blurred by decades of hybridisation that the terms describe marketing categories more than distinct plant species. The direction of effects (“indica for body/sedation, sativa for head/energy”) is loosely correlated with certain terpene profiles but is not a reliable pharmacological prediction. More meaningful variables include THC concentration, CBD concentration, terpene profile, route of administration, dose, and the individual user's biology, history, and state. A product's cannabinoid and terpene test results, where available, are more informative than its marketing category.
Subjective effects from smoked cannabis typically peak within 30–60 minutes and diminish substantially by 2–4 hours. However, measurable cognitive impairment — affecting reaction time, memory, and decision-making — can persist significantly beyond the subjective high, particularly with high-potency products and in regular users who may not feel impaired while cognitively affected. Driving should be avoided for at least 4–6 hours after smoking and significantly longer after edibles. Regular heavy users may have persistent low-level impairment that lasts days after cessation. THC and its metabolites are detectable in urine for days to weeks depending on frequency of use, though detection does not indicate current impairment.